BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhuang X, Zhao C, Li J, Su C, Chen X, Ren S, Li X, Zhou C. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF. Cancer Med 2019;8:2858-66. [PMID: 31016879 DOI: 10.1002/cam4.2183] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Guan M, Xu J, Shi Q. Molecular determinants of clinical outcomes for anaplastic lymphoma kinase-positive non-small cell lung cancer in Chinese patients: A retrospective study. Cancer Genet 2023;270-271:32-8. [PMID: 36502690 DOI: 10.1016/j.cancergen.2022.11.005] [Reference Citation Analysis]
2 Sobreira da Silva MJ, Serpa Osorio-de-Castro CG, Paes RD, Negrete CL, Eugênio E, Moraes EL, Livinalli A. Potential interactions between antineoplastic agents and medicines used to treat Covid-19. J Oncol Pharm Pract 2022;28:1737-48. [PMID: 34637360 DOI: 10.1177/10781552211040494] [Reference Citation Analysis]
3 Zhong WX, Wei XF. Coexistence of anaplastic lymphoma kinase rearrangement in lung adenocarcinoma harbouring epidermal growth factor receptor mutation: A single-center study. World J Clin Cases 2022; 10(33): 12164-12174 [DOI: 10.12998/wjcc.v10.i33.12164] [Reference Citation Analysis]
4 Liu Y, Gao Y, Wang Y, Zhao C, Zhang Z, Li B, Zhang T. A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice. BMC Cancer 2022;22:1175. [DOI: 10.1186/s12885-022-10236-9] [Reference Citation Analysis]
5 Chen S, Guan L, Zhao X, Yang J, Chen L, Guo M, Zhao J, Chen C, Zhou Y, Han Y, Xu L. Optimized thyroid transcription factor-1 core promoter-driven microRNA-7 expression effectively inhibits the growth of human non-small-cell lung cancer cells. J Zhejiang Univ Sci B 2022;23:915-930. [DOI: 10.1631/jzus.b2200116] [Reference Citation Analysis]
6 Sforza V, Palumbo G, Cascetta P, Carillio G, Manzo A, Montanino A, Sandomenico C, Costanzo R, Esposito G, Laudato F, Damiano S, Forte CA, Frosini G, Farese S, Piccirillo MC, Pascarella G, Normanno N, Morabito A. BRAF Inhibitors in Non-Small Cell Lung Cancer. Cancers 2022;14:4863. [DOI: 10.3390/cancers14194863] [Reference Citation Analysis]
7 Chen P, Liu Y, Wen Y, Zhou C. Non-small cell lung cancer in China. Cancer Commun (Lond) 2022. [PMID: 36075878 DOI: 10.1002/cac2.12359] [Reference Citation Analysis]
8 Soeroso NN, Ananda FR, Sitanggang JS, Vinolina NS. The role of oncogenes and tumor suppressor genes in determining survival rates of lung cancer patients in the population of North Sumatra, Indonesia. F1000Res 2022;11:853. [DOI: 10.12688/f1000research.113303.1] [Reference Citation Analysis]
9 Qu J, Shen Q, Li Y, Kalyani FS, Liu L, Zhou J, Zhou J. Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients With the BRAF-V600E Mutation. Front Oncol 2022;12:911303. [DOI: 10.3389/fonc.2022.911303] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Lei Y, Wang K, Liu Y, Wang X, Xiang X, Ning X, Ding W, Duan J, Li D, Zhao W, Li Y, Zhang F, Luo X, Shi Y, Wang Y, Huang D, Bai Y, Zhang H. Various Subtypes of EGFR Mutations in Patients With NSCLC Define Genetic, Immunologic Diversity and Possess Different Prognostic Biomarkers. Front Immunol 2022;13:811601. [PMID: 35265073 DOI: 10.3389/fimmu.2022.811601] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Deng Y, Chen X, Huang C, Song J, Feng S, Chen X, Zhou R, Wang F. Screening and Validation of Significant Genes with Poor Prognosis in Pathologic Stage-I Lung Adenocarcinoma. Journal of Oncology 2022;2022:1-17. [DOI: 10.1155/2022/3794021] [Reference Citation Analysis]
12 Sunaga N, Miura Y, Kasahara N, Sakurai R. Targeting Oncogenic KRAS in Non-Small-Cell Lung Cancer. Cancers (Basel) 2021;13:5956. [PMID: 34885068 DOI: 10.3390/cancers13235956] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
13 Chang F, Zhang H, Chen C, Ke Z, Zhao M, Fan X, Zhang Y. Concomitant genetic alterations are associated with plasma D-dimer level in patients with non-small cell lung cancer. Future Oncol 2021. [PMID: 34789015 DOI: 10.2217/fon-2021-0455] [Reference Citation Analysis]
14 Tang H, Pang P, Qin Z, Zhao Z, Wu Q, Song S, Li F. The CPNE Family and Their Role in Cancers. Front Genet 2021;12:689097. [PMID: 34367247 DOI: 10.3389/fgene.2021.689097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
15 Berzenji L, Debaenst S, Hendriks JMH, Yogeswaran SK, Lauwers P, Van Schil PE. The role of the surgeon in the management of oligometastatic non-small cell lung cancer: a literature review. Transl Lung Cancer Res 2021;10:3409-19. [PMID: 34430376 DOI: 10.21037/tlcr-21-58] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
16 Gristina V, La Mantia M, Galvano A, Cutaia S, Barraco N, Castiglia M, Perez A, Bono M, Iacono F, Greco M, Calcara K, Calò V, Rizzo S, Incorvaia L, Lisanti MC, Santanelli G, Sardo D, Inguglia S, Insalaco L, Castellana L, Cusenza S, Pantuso G, Russo A, Bazan V. Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma. JMP 2021;2:173-96. [DOI: 10.3390/jmp2020016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
17 Kim JH, Yoon S, Lee DH, Jang SJ, Chun SM, Kim SW. Real-world utility of next-generation sequencing for targeted gene analysis and its application to treatment in lung adenocarcinoma. Cancer Med 2021;10:3197-204. [PMID: 33960703 DOI: 10.1002/cam4.3874] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
18 Lan Z, Zhang X, Ma X, Hu Y, Zhang J, Yang F. Utility of liquid-based cytology on residual needle rinses collected from core needle biopsy for lung nodule diagnosis. Cancer Med 2021;10:3919-27. [PMID: 33963680 DOI: 10.1002/cam4.3949] [Reference Citation Analysis]
19 Zhang Z, Yang L, Li Y, Wu Y, Li X, Wu X. Four long noncoding RNAs act as biomarkers in lung adenocarcinoma. Open Med (Wars) 2021;16:660-71. [PMID: 33981850 DOI: 10.1515/med-2021-0276] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Liu Y, Li H, Zhu J, Zhang Y, Liu X, Li R, Zhang Q, Cheng Y. The Prevalence and Concurrent Pathogenic Mutations of KRAS G12C in Northeast Chinese Non-small-cell Lung Cancer Patients. Cancer Manag Res 2021;13:2447-54. [PMID: 33758543 DOI: 10.2147/CMAR.S282617] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
21 Guo X, Zhao J, Du Y, Liu Y, Ma Y, Wang R, Ji X, Wu J, Dong L. Using Disposable Membrane Cell Collector to Enrich Lung Adenocarcinoma Cells in Bloody Pleural Effusion for Anaplastic Lymphoma Kinase Fusion Gene Detection. Acta Cytol 2021;65:235-41. [PMID: 33631757 DOI: 10.1159/000512868] [Reference Citation Analysis]
22 Meng P, Rybczynska AA, Wei J, Terpstra MM, Timens W, Schuuring E, Hiltermann TJN, Groen HJ, van der Wekken AJ, van den Berg A, Kok K. Detecting therapy-guiding RNA aberrations in platelets of non-small cell lung cancer patients.. [DOI: 10.1101/2021.01.26.21250013] [Reference Citation Analysis]
23 Nardo G, Carlet J, Marra L, Bonanno L, Boscolo A, Dal Maso A, Boscolo Bragadin A, Indraccolo S, Zulato E. Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors. Front Oncol 2020;10:607840. [PMID: 33520716 DOI: 10.3389/fonc.2020.607840] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
24 Guo Y, Song J, Wang Y, Huang L, Sun L, Zhao J, Zhang S, Jing W, Ma J, Han C. Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review. Front Oncol 2020;10:610923. [PMID: 33363040 DOI: 10.3389/fonc.2020.610923] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
25 Zhao C, Jiang T, Li J, Wang Y, Su C, Chen X, Ren S, Li X, Zhou C. The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer. Transl Lung Cancer Res 2020;9:1149-58. [PMID: 32953493 DOI: 10.21037/tlcr-19-359] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
26 Li D, Ding L, Ran W, Huang Y, Li G, Wang C, Xiao Y, Wang X, Lin D, Xing X. Status of 10 targeted genes of non-small cell lung cancer in eastern China: A study of 884 patients based on NGS in a single institution. Thorac Cancer 2020;11:2580-9. [PMID: 32729257 DOI: 10.1111/1759-7714.13577] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
27 Dang AH, Tran VU, Tran TT, Thi Pham HA, Le DT, Nguyen L, Nguyen NV, Thi Nguyen TH, Nguyen CV, Le HT, Thi Nguyen ML, Le VT, Nguyen PH, Vo BT, Thi Dao HT, Nguyen LT, Van Nguyen TC, Bui QN, Nguyen LH, Nguyen NH, Thi Nguyen QT, Le TX, Do TT, Dinh KT, Do HN, Phan MD, Nguyen HN, Tran LS, Giang H. Actionable Mutation Profiles of Non-Small Cell Lung Cancer patients from Vietnamese population. Sci Rep 2020;10:2707. [PMID: 32066856 DOI: 10.1038/s41598-020-59744-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
28 Gao L, Yan SB, Yang J, Kong JL, Shi K, Ma FC, Huang LZ, Luo J, Yin SY, He RQ, Hu XH, Chen G. MiR-182-5p and its target HOXA9 in non-small cell lung cancer: a clinical and in-silico exploration with the combination of RT-qPCR, miRNA-seq and miRNA-chip. BMC Med Genomics 2020;13:3. [PMID: 31906958 DOI: 10.1186/s12920-019-0648-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
29 Aran V, Omerovic J. Current Approaches in NSCLC Targeting K-RAS and EGFR. Int J Mol Sci 2019;20:E5701. [PMID: 31739412 DOI: 10.3390/ijms20225701] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 6.5] [Reference Citation Analysis]
30 Colombino M, Paliogiannis P, Cossu A, Santeufemia DA, Sini MC, Casula M, Palomba G, Manca A, Pisano M, Doneddu V, Palmieri G; Sardinian Lung Cancer (SLC) Study Group. EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma. BMC Pulm Med 2019;19:209. [PMID: 31711449 DOI: 10.1186/s12890-019-0964-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
31 Cai D, Hu C, Li L, Deng S, Yang J, Han-Zhang H, Li M. The prevalence and prognostic value of KRAS co-mutation subtypes in Chinese advanced non-small cell lung cancer patients. Cancer Med 2020;9:84-93. [PMID: 31709742 DOI: 10.1002/cam4.2682] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
32 Zhou X, Shou J, Sheng J, Xu C, Ren S, Cai X, Chu Q, Wang W, Zhen Q, Zhou Y, Li W, Pan H, Li H, Sun T, Cheng H, Wang H, Lou F, Rao C, Cao S, Pan H, Fang Y. Molecular and clinical analysis of Chinese patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer. Cancer Sci 2019;110:3382-90. [PMID: 31444835 DOI: 10.1111/cas.14177] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
33 Zhuang X, Zhao C, Li J, Su C, Chen X, Ren S, Li X, Zhou C. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF. Cancer Med 2019;8:2858-66. [PMID: 31016879 DOI: 10.1002/cam4.2183] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 7.5] [Reference Citation Analysis]